Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Cemdisiran (Primary) ; Pozelimab (Primary)
- Indications Myasthenia gravis
- Focus Registrational; Therapeutic Use
- Acronyms NIMBLE
- Sponsors Regeneron Pharmaceuticals
- 28 Jun 2024 Planned primary completion date changed from 29 Aug 2025 to 21 May 2025.
- 07 Mar 2024 Planned End Date changed from 1 May 2027 to 23 Mar 2028.
- 07 Mar 2024 Planned primary completion date changed from 14 Aug 2024 to 29 Aug 2025.